IYXI Inyx Inc (CE)

TEAMM Pharmaceuticals, Inc., the specialty pharmaceutical division of Accentia BioPharmaceuticals, Inc. (NASDAQ:ABPI), and Exaeris, Inc., the wholly owned subsidiary of Inyx, Inc. (OTC:BB:IYXI), announced today that they have finalized a co-promotion agreement through which the companies will co-market the MD Turbo(TM), a novel breath-activated, dose-counting companion to meter dose inhalers (MDIs). MD Turbo will be available by prescription in the U.S. later this quarter. MD Turbo is the first commercialized product specifically designed to coordinate inspiration and MDI activation using patented i-Point(TM) technology. The technology enables the majority of the MDIs used today to trigger their delivery through breath-activation, helping ensure the labeled dose is delivered at the appropriate time. The product contains an electronic dose counter to help patients improve medication compliance by tracking the number of doses remaining before a refill is required. The combination of the two key features - breath activation and dose counting - addresses two of the biggest challenges in MDI use. There are more than 40 million MDI prescriptions written annually in the United States for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Inhalers deliver the drug directly into the lungs, but the currently available products rely upon a patient's precise coordination of inhaler activation and inhalation. Studies have shown that over 50% of patients incorrectly time the release of medication from these traditional inhalers.(1,2,3) MD Turbo's breath activation and electronic dose counting is intended to make the use of MDIs easier and more accurate for asthma and COPD patients of all ages. Gary Cantrell, Executive Vice President of Sales and Marketing for TEAMM commented: "We see tremendous synergies between TEAMM and Exaeris, and we are delighted to have Exaeris as a partner on this important launch. We recognized early in our planning process that MD Turbo was going to fulfill an unmet and critical need for asthmatic and COPD patients, and we needed to get our message out to the appropriate healthcare professionals. Impressed with the respiratory specialty company that Exaeris had built, we realized that the combination of Exaeris and TEAMM's sales forces would allow us to reach the majority of physicians and healthcare professionals currently treating asthmatic and COPD patients. With this agreement, our partnership has been officially established, and we look forward to a long relationship with Exaeris." Stephen Beckman, President of Exaeris, added: "Exaeris' corporate mission is to help improve outcomes for the treatment of respiratory diseases. MD Turbo is an exciting addition to our product mix and one that will satisfy a well-defined need in the marketplace. The partnership with TEAMM ensures that the appropriate level of product awareness, patient education and customer support will reach the individuals who will benefit most from the product. We are delighted to be associated with TEAMM in this endeavor." (1) Pederson S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy. 1986;46: 118-124. (2) Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis. 1982;63(suppl 119):101-104. (3) Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest.1993;104(5):1332-1336. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. Two of these products are SinuNase(TM) and BiovaxID(TM). The Company's SinuNase product, in development to treat chronic sinusitis (rhinosinusitis), is a novel application and formulation of a known anti-fungal licensed from the Mayo Foundation for Medical Education and Research. BiovaxID is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed by Accentia's subsidiary Biovest International, Inc., is currently in a Phase 3 clinical trial. In addition, Accentia's growing specialty pharmaceutical business, TEAMM Pharmaceuticals Inc., has a portfolio of currently marketed products plus a pipeline of additional products under development by third parties. For further information, please visit our web site: www.accentia.net. About Exaeris, Inc. Exaeris is a wholly owned subsidiary of Inyx, located in Exton, PA. Exaeris is the commercial arm of Inyx and markets a range of respiratory products acquired through key strategic partnerships and internal development. About Inyx, Inc. Inyx is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services. In addition, Inyx is developing its own proprietary products to be marketed by Exaeris and strategic partners. The company's operations are conducted through several other wholly owned subsidiaries, including: Inyx USA, Ltd., based in Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe Limited, which owns and operates Ashton Pharmaceuticals Ltd., all near Manchester, England; and Inyx Canada, Inc. in Toronto. Inyx, Inc.'s corporate offices are in New York City. For more information, please visit: www.inyxinc.com. Forward-Looking Statements Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Accentia, Inyx, their respective operations and any other statements relating to their respective products, product candidates, regulatory approval, product launches and product development programs. Such statements may include, without limitation, statements with respect to each of the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia and/or Inyx to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in Accentia's and Inyx's respective filings with the Securities and Exchange Commission. All forward looking statements are qualified in their entirety by this cautionary statement, and Accentia and Inyx does not undertake any obligation to revise or update this news release to reflect events or circumstances after the date hereof.